Last reviewed · How we verify
PPI-668
At a glance
| Generic name | PPI-668 |
|---|---|
| Sponsor | Presidio Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF
- 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C (PHASE2, PHASE3)
- Strategic Transformation of the Market of HCV Treatments (PHASE2, PHASE3)
- A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers (PHASE1)
- Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan (PHASE2)
- Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects. (PHASE2, PHASE3)
- A Phase 1 Bioequivalence Study of a Test Tablet Formulation of Ravidasvir With the Reference Tablet Formulation of Ravidasvir Study (PHASE1)
- Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PPI-668 CI brief — competitive landscape report
- PPI-668 updates RSS · CI watch RSS
- Presidio Pharmaceuticals, Inc. portfolio CI